Monopar Therapeutics (MNPR) Change in Cash (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Change in Cash data on file, last reported at -$65.8 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Cash fell 265.45% year-over-year to -$65.8 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (down 58.45% YoY), and the FY2025 full-year result was $16.0 million, down 58.45% from the prior year.
• Change in Cash retreated to -$65.8 million in Q4 2025, from $88.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $88.2 million in Q3 2025 to a low of -$65.8 million in Q4 2025.
• A 5-year average of $2.3 million and a median of -$1.6 million in 2021 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash plunged 2997.62% in 2021 and surged 88410.54% in 2025, its largest moves.
• Tracing MNPR's Change in Cash over 5 years: stood at -$2.0 million in 2021, then sank by 200.84% to -$6.1 million in 2022, then soared by 128.56% to $1.8 million in 2023, then soared by 2173.12% to $39.8 million in 2024, then sank by 265.45% to -$65.8 million in 2025.
• Business Quant data shows MNPR's Change in Cash at -$65.8 million in Q4 2025, $88.2 million in Q3 2025, and -$209473.0 in Q2 2025.